A PROCESS FOR THE PREPARATION OF DERIVATIVES OF 2-DIETHYLAMINO-1-METHYL ETHYL CIS-1-HYDROXY-(BICYCLOHEXYL)-2-CARBOXYLATE

Abstract: For the preparation of derivatives of 2-diethylamino-1-­ methylethyl cis-1-hydroxy-(bicyclohexyl)-2-carboxylate, par­ ticularly citrate, maleate, fumarate and pamoate, the oily base is previously converted to the phosphate, whereby solid products are obtained, both soluble and insoluble in water.

Description: The present invention relates to pharmaceutically acceptable salts of 2-diethylamino1-methylethyl c -1-hydroxy-(bicyclohexyl)-2-carboxylate and particularly to a process for their preparation. The 2 -diethy lamino -l-methy le thy 1 cis-1 -hydroxy -(b icyc lohexy l)-2 -carbox y late, also known with the common international name of Rociverine or "Rociverinum", is an active principle known and used in therapy as antispastic drug (U.K. Patent No. 1.167.386). It is prepared by reacting cffis-1-hydroxy-(biciclohexyl)-2carboxylic acid with 1diethylamino-2-chloropropane in the presence of an acceptor of hydrogen chloride; by this reaction a mixture of position isomers is formed, from which through a thermal treatment, causing an isomerization to take place, and a purification by distillation (see Italian Patent Application No. 30163 A/78), the therapeutically active and desired isomer is obtained, having the formula: EMI1.1 The thus obtained product is in form of a yellow oily liquid, not soluble in water, having a gaschromatographic purify of 98%, which is used as such in the pharmaceutical practice for the preparation of vials, tablets and suppositories. Of course, for the purposes of a pharmaceutical use, an oily substance is of more difficult handling, both in the preparation of the desired formulations, and as regards the storage, unless particular cautions are taken. The main purpose of the present invention is that of providing a process permitting the subject active principle to be obtained in form of a solid having purity higher than 99%, with physical properties suitable for the therapeutical use, namely either soluble in water for readily absorbable preparations or poorly soluble for delayed release compositions. Another purpose of the present invention is that of providing a process permitting the preparation of a pharmaceutically acceptable solid salt, also starting from the reaction mixture, as resulting from the preparation of the active principle as previously mentioned, after the thermal treatment, whereby the purification by distillation is no longer needed. These and other purposes are achieved by a process comprising reacting 2 diethylamino-1 -methylethyl cis-1 hydroxy-(bycyclohexyl)-2-carboxy late with phosphoric acid in an organic solvent and at low temperature, extracting with an organic solvent the base from the alkalinized aqueous solution and salifying with pharmaceutically acceptable organic acids, in an organic solvent and at low temperature, or by treatment of the aqueous solution of the phosphate salt of rociverine with an aqueous solution of disodium pamoate. The process is based on the salification with phosphoric acid, dissolved in a suitable solvent, for instance acetone, of the rociverine base, either raw or distilled, the latter being also dissolved in a suitable solvent. By cooling a white crystalline solid is obtained, hyghly soluble in water, stable and not hygroscopic, having melting point of 89-920C and gaschromatographic purity higher than 99%. The pharmaceutically useful salts of rociverine, with a purity higher than 99%, are obtained by starting from rociverine phosphate, extracting with a suitable solvent, for instance ethyl ether, the base after alkalinization of the aqueous solution of the phosphate, salifying with the desired acid, in anhydrous form, dissolved in a suitable solvent, for instance acetone, and cooling; the salt with pamoic acid is obtained by mixing the aqueous solution of rociverine phosphate with the aqueous solution of disodium pamoate. In the case of the rociverine citrate, a white powder, highly soluble in water and very little hygroscopic, is obtained, having melting poing of 82-840C and gaschromatographic purity higher than 99%. In the case of rociverine maleate, there is obtained a white crystalline powder, highly soluble in water and very little hygroscopic, having melting point of 79-810C. In the case of rociverine fumarate, there is obtained a white crystalline powder, soluble in water and non hygroscopic, having melting point of 111-113 C. In the case of rociverine pamoate, there is obtained a white powder, not soluble in water, non hygroscopic and having melting point of 103-1050C. The following examples, having only illustrative but non limiting purpose, detailedly describe the process of the invention with reference to the citrate, it being understood that for the other pharmaceutically acceptable salts (apart from pamoate) the process is carried out likewise. EXAMPLE 1 In a three-neck flask, having stirrer and drop fummel, 339 g of 2-(diethylamino).1- me thyle thy 1 cis-l-hydroxy-(b icyclohexyl)-2 -carboxyiate (roc iverine) are dissolved in 250 mis of acetone and the flask is placed in a refrigerating bath at a temperature of between 0 C and -200C. There are dropwise added under stirring over about 30 minutes 115 g of 85% phosphoric acid dissolved in 300 mls of acetone. Upon completion of the addition, the mixture is stirred for 2 hours. The precipitated product is filtered, washed with acetone and dried in an oven under vacuum. Rociverine phosphate is obtained as a microcrystalline solid having melting point of 89-920C with gaschromatographic titre of 99% and a yield of 93%. EXAMPLE 2 432 g of rociverine phosphate are dissolved in 2 parts of water, and the mixture is alkalinized with aqueous solution of sodium hydroxide and extracted with a suitable solvent, for instance ethyl ether; the ether is then dried over anhydrous sodium sulphate, cooled to 0 to 50C, and added under stirring with 192 g of citric acid dissolve in the minimum amount of acetone. The mixture is maintaned under stirring for a minimum of 2 hours, so as to permit the salt to completely precipitate, filtered, washed with the same solvent and dried under vacuum. There is thus obtained a yield higher that 95% of rociverine citrate in form of a white powder, very little hygroscopic, having melting point of 82-840C and a gaschromatographic purity higher than 99%. EXAMPLE 3 Starting again from 432 g of rociverine the process of example 2 is repeated, by adding under stirring to the ethereal solution of the base, cooled at OOC to 5tC, 116 g of fumaric acid (or 116 g of maleic acid) dissolved in the minimum amount of acetone. The isolation is then carried out as described in example 2, giving place in this case to a yield higher than 95% of rociverine fumarete as a white, non hygroscopic powder, having melting point of lll-1130C and gaschromatographic purity higher than 99%; in the case of maleic acid there is obtained a white crystalline powder, very little hygroscopic, having melting point of 79 to 81doc. EXAMPLE 4 A solution of 432 g of rociverine phosphate in 20 parts of water is slowly added under stirring with a solution obtained by dissolving 194,2 g of pamoic acid in 3 litres of water containing 40 g of NaOH. The thus formed precipitate is collected and washed by suspending it again in water. The mixture is filtered giving place, with a yield of 95%, to a yellowish powder comprising a compound formed by two molecules of rociverine and one molecule of pamoic acid, with a melting point of 103-105oC. It is important to point out that the rocivering phosphate has no substantial therapeutical properties, whereby the preparation thereof would not have had any therapeutical purpose. Likewis it might not be supposed that by preparing the phosphate salt and then coverting it into another pharmaceutically acceptable salt, as the citrate, the purposes of the preeoni invention would be achieved, whereas the direct preparation of rociverine citrate was giving place to a product having different properties and physical characteristics. Furthermore the process of the inveniton, namely the step of conversion to the phosphate permits novel compounds to be prepared, which are therapeutically interesting, namely fumarate, maleate and pamoate, wich are not directly obtainable from the base, even if distilled.

Claims: CLAIMS 1) A process for the preparation of pharmaceutically acceptable derivatives of 2 diethylamino-l -methylethyl cis-1-hydroxy-(bicyclohexyl)-2-carboxylate, characterized in that the phosphate of 2-diethylamino-1-methyiethyl cis-1-hydroxy-(biciclohe- xyl).2.carboxylate is prepared, and then the phosphate is converted to the desired derivative. 2) A process according to claim 1, characterized in that 2-diethylamino-1 methylethyl c is -hydroxy -(b icye lohexy l)-2-carboxy la te is reacted with phosphoric acid in an organic solvent and at low temperature the resulting precipitate is made alkaline and extracted with an organic solvent and thereafter the salification is carried out with an anhydrous organic acid, in an organic solvent and at low temperature, said acid being selected among citric, maleic and fumaric acid. 3) A process according to claim 2, characterized in that the reaction with phosphoric acid is carried out in acetone and the reaction temperature is of between 0 C and 20 C. 4) A process according to claim 2,characterized in that said alkalinization is carried out with an alkali hydroxide and said extraction is carried out with ethyl ether. 5) A process according to claim 2, characterized in that the salification reaction is carried out with citric acid in acetone and at a temperature of between O0C and 5 C 6) A process according to claim 1, characterized in that 2-diethylamino-1 me thy lethyl cis-1 -hydroxy.(bicyclohexyl).2 -carboxylate is reacted with phosphoric and in an organic solvent and at low temperature, and the resulting precipitate is reacted with a salt of pamoic acid with a strong base in alkaline medium. 7) Phosphate of 2-diethylamino-1 -me thy lethyl cis-l-hydroxy -(biciclohexyl)-2-carboxy- late. 8) Fumarate of 2-diethylamino-1-methylethyl cis-l-hydroxy-(b icyclohexyl)-2-carboxy- late. 9) Maleate of 2-diethylamino.1.methylethyl cis-1 .hydroxy.(bicyclohexyl).2-carboxy. late. 10) Pamoate of 2-diethylamino-1 -methylethyl cis-1-hydroxy-(biciclohexyl)-2-carboxy- late.

Inventors: SBARBARO, FRANCO
Applicants: LABORATORI GUIDOTTI S.P.A.
Application year: 1983
Main classification: C07C93
IPC codes: C07C213, C07C219, C07C67